People · Operator
Named in public records as an officer, director or promoter · active 2009–2024 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Alumis Inc. | — | Biotechnology | Series D+ | $240.0M | $432.7M | 2024 |
| Achaogen Inc | — | Biotechnology | Series B | $89.7M | $396.9M | 2016 |
| Gloucester Pharmaceuticals Inc | — | Biotechnology | Series B | $26.0M | $806.7M | 2009 |
Alan B. Colowick at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Alan B. Colowick on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Seth Harrison | 1 | 19 |
| Srinivas Akkaraju | 1 | 10 |
| Richard Gaster | 1 | 7 |
| David Schnell | 1 | 7 |
| Alan Colowick | 1 | 7 |
| Bryan E. Roberts | 1 | 6 |
| James Tananbaum | 1 | 6 |
| Thomas Dyrberg | 1 | 5 |
| Robert J. More | 1 | 4 |
| Jay Moorin | 1 | 4 |
| James B. Tananbaum | 1 | 4 |
| June Lee | 1 | 3 |
| Donald J Hayden | 1 | 3 |
| Michael Rome | 1 | 3 |
| Mark Bradley | 1 | 3 |
| Martin Vogelbaum | 1 | 3 |
| Sapna Srivastava | 1 | 3 |
| Christopher T. Walsh | 1 | 3 |
| Vikram Bajaj | 1 | 3 |
| John R. Schroer | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.